top of page

Business 

Business model focused on both internal development and licensing

INTERNAL PRODUCT DEVELOPMENT

INTERNAL TECHNOLOGY DEVELOPMENT

EXTERNAL LICENSING AND CO-DEVELOPMENT

        Oral
        Parenteral
        Drug Combinations
        Multiple Industries

Clinical Trials and/or Asset Sales

Licensing, milestones, royalties

Multiple partners
Multiple solutions
Multiple products
Multiple industries

POx SOLUBILIZED PACLITAXEL IMPROVES UPON STANDARD OF CARE - ABRAXANE ®

image.png

  1. POxOral: New IP filed 2024. Dramatic increase in oral bioavailability outperforming all other oral paclitaxel formulations. 505b2 regulatory approach possible to decrease development costs and time to approval.              

  2. POxol injection: Increases potency and convenience while decreasing cost over slow infusion required for Abraxane. Demonstrated to be 505b2 bioequivalent to Abraxane in primates.                                                                     

  3. CombiPOx: Simplifies development for Combination Therapies with multiple drugs to provide improved anti-tumor activity and greater convenience. Several indications and drug combinations in progress.

bottom of page